Results 71 to 80 of about 20,698 (251)

Semaglutide attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis of cardiomyocytes via activation of PKC-S100A9 axis

Frontiers in Pharmacology
ObjectiveThe incidence of ischemic cardiomyopathy increases annually worldwide, and it is the leading cause of mortality in China. Although interventional diagnostic and therapeutic techniques can promptly open the culprit vessels, myocardial ischemia ...
Yan Liu, Zixuan Li, Xinhe Xu, Yan Zou, Miaomiao Zhang, Yingyu Chen, Wenwu Zhu, Bing Han   +7 more
doaj   +1 more source

The Needle‐Free Frontier: Redefining the Limits of Transdermal Insulin Delivery

Exploration, EarlyView.
Wei and colleagues reported a pH‐responsive, charge‐switchable polyzwitterionic polymer carrier that achieves non‐invasive transdermal insulin delivery without external energy input. The approach leverages adaptive compatibility with the cutaneous microenvironment to shuttle functional macromolecules across intact skin and achieve definitive systemic ...
Junge Chen, Yuxuan Liu, Bozhang Xia, Julien Milon Essola, Xing‐Jie Liang   +4 more
wiley   +1 more source

Protective Effect of Semaglutide on Obesity-Induced Renal Disease and Obesity-Induced Kidney Renal Clear Cell Carcinoma [PDF]

Shuqi Wang,1,2 Mengmeng Zhang,1,2 Xiaoman Yang,1,2 Shuchun Chen1– 3 1Department of Internal Medicine, Hebei Medical University, Shijiazhuang, People’s Republic of China; 2Department of Endocrinology, Hebei General Hospital, Shijiazhuang, People’s ...
Yang X, Wang S, Zhang M, Chen S
core  

Surgically confirmed severe endometriosis is associated with lower risk of steatotic liver disease: Evidence of estrogen‐linked hepatic–reproductive crosstalk

International Journal of Gynecology &Obstetrics, EarlyView.
Severe surgically confirmed endometriosis was associated with a lower prevalence of steatotic liver disease than non‐severe disease. Higher estradiol levels may partly explain this inverse hepatic–reproductive association, supporting integrated gynecologic and hepatologic risk assessment.
Jung Hyun Park, Keungmo Yang, Hyun Yang, Si Hyun Bae, Mee‐Ran Kim, Jaejun Lee   +5 more
wiley   +1 more source

High‐Throughput Quantitative Chemical Shift‐Encoded MRI of the Liver

Journal of Magnetic Resonance Imaging, EarlyView.
ABSTRACT Background Access to MRI is limited by lengthy exam times and inefficient utilization. Focused protocols can reduce exam times, but workflow variability and inefficient room turnaround contribute to conservative scheduling with long exam slots.
Garrett C. Fullerton, Jiayi Tang, Jitka Starekova, Julius F. Heidenreich, Ali Pirasteh, David T. Harris, Daiki Tamada, Collin J. Buelo, Dan W. Rettmann, Diego Hernando, Scott B. Reeder   +10 more
wiley   +1 more source

Semaglutide-Induced Liver Injury

Semaglutide, a glucagon-like peptide-1 receptor agonist widely used for managing type 2 diabetes mellitus and obesity. Reports of semaglutide-associated hepatotoxicity are exceedingly rare.
Bassi, Raghav, Brar, Tony S., Kalsi, Harsimran, Perbtani, Yaseen, Akhavan, Neeka, Brar, Tony, Essilfie-Quaye, Kobina, Arora, Samneet Singh   +7 more
core   +1 more source

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source

Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial

BMJ Open Diabetes Research & Care
Introduction This study evaluated the long-term effectiveness of once-weekly subcutaneous semaglutide versus alternative treatment in adults with type 2 diabetes (T2D) in routine clinical practice.Research design and methods The SEmaglutide PRAgmatic ...
John B Buse, Helene Nordahl Christensen, Brian J Harty, Vincent J Willey, Mark J Cziraky, Simon Skibsted   +5 more
doaj   +1 more source

Association of Glucagon‐Like Peptide—1 Receptor Analogues and Laryngeal Symptoms in Obese Adults

The Laryngoscope, EarlyView.
Table 1 succinctly quantifies the time‑dependent association between GLP‑1RA/GIP therapy and laryngeal symptoms, demonstrating modest but statistically robust increases in outcomes such as cough and voice/resonance disorders by 6 months. It provides clinically actionable absolute risks, odds ratios, and hazard ratios that can directly inform counseling,
Priyanka Shah, David Kayekjian, Shaun A. Nguyen, Kirsten Meenan, Ashli K. O’Rourke   +4 more
wiley   +1 more source

Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia

Saudi Pharmaceutical Journal
Introduction: Semaglutide, a Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA), is often prescribed for managing type 2 diabetes, particularly in cases unresponsive to other hypoglycemic agents.
Yazed AlRuthia, Khaled Hani Aburisheh, Sondus Ata, Raghad Bin Salleeh, Shahad B. Alqudhibi, Raghad B. Alqudhibi, Ziad Alkraidis, Hala Humood Alkhalaf, Abdulrahman Abdullah Almogirah, Muhammad Mujammami, Reem Al Khalifah   +10 more
doaj   +1 more source